Synthesis, ADMET predictions, molecular docking studies, and
Antineoplastic Agents
/ pharmacology
Benzoxazines
/ pharmacology
Cell Line, Tumor
Cell Proliferation
/ drug effects
Drug Screening Assays, Antitumor
ErbB Receptors
Humans
Lung Neoplasms
/ drug therapy
Molecular Docking Simulation
Molecular Structure
Spectroscopy, Fourier Transform Infrared
Structure-Activity Relationship
A549 cancer cell
ADMET prediction
benzoxazines
molecular docking
synthesis
Journal
Journal of basic and clinical physiology and pharmacology
ISSN: 2191-0286
Titre abrégé: J Basic Clin Physiol Pharmacol
Pays: Germany
ID NLM: 9101750
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
28
11
2020
accepted:
03
03
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
18
12
2021
Statut:
epublish
Résumé
This study aims to synthesize a series of benzoxazines ( Benzoxazines ( Compounds Compound (
Identifiants
pubmed: 34214332
pii: jbcpp-2020-0433
doi: 10.1515/jbcpp-2020-0433
doi:
Substances chimiques
Antineoplastic Agents
0
Benzoxazines
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-392Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
The Global Cancer Observatory. Indonesia fact sheet. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf [Accessed 1 May 2019].
Gillian, B, Drew, B, Neale, R, Zhaolin, X. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis 2010;2:48–51.
Sousa, AC, Silveira, C, Janeiro, A, Malveiro, S, Oliveira, AR, Felizardo, M, et al.. Detection of rare and novel EGFR mutations in NSCLC patients: implications for treatment-decision. Lung Canc 2020;139:35–40.
Grigoriu, B, Berghmans, T, Meert, AP. Management of EGFR mutated nonsmall cell lung carcinoma patients. Eur Respir J 2015;45:1132–41.
Kesuma, D, Putra, GS, Yuniarta, TA, Sulistyowaty, MI, Siswandono, BT. Synthesis of 2-phenyl-4H-benzo[d][1,3]oxazin-4-one and its biological activity against A549 cancer cell line through methionyl-tRNA synthetase inhibition approach on in-silico studies. Int J Pharmaceut Res 2019;11:1–11.
El-Azab, Adel, S, Al-Omar, MA, Abdel-Aziz, AAM, Abdel-Aziz, NI, El-Sayed, MAA, et al.. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study. Eur J Med Chem 2010;45:4188–98.
Bharathkumar, H, Mohan, CD, Rangappa, S, Kang, T, Keerthy, HK, Fuchs, JE, et al.. Screening of quinoline, 1,3-benzoxazine, and 1,3-Oxazine-based small molecules against isolated methionyl-tRNA synthetase and A549 and HCT116 cancer cells including an in silico binding mode analysis. Org Biomol Chem 2015;36:1–21.
Jiao, P-F, Zhao, B-X, Wang, W-W, He, Q-X, Wan, M-S, Shin, D-S, et al.. Design, synthesis, and preliminary biological evaluation of 2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine derivatives. Bioorg Med Chem Lett 2006;16:2862–7.
Su, H, Su, L, He, Q, Zhao, J, Zhao, B, Zhang, S, et al.. A benzoxazine derivative specifically inhibits cell cycle progression in p53-wild type pulmonary adenocarcinoma cells. Front Biol 2010;5:180–6.
Putra, GS, Widiyana, AP, Muchlashi, LA, Sulistyowaty, MI, Ekowati, J, Budiati, T. The influence of ratio pyridine and triethylamine catalysts on synthesis 2-phenyl-benzo[D] [1,3] oxazine-4-on derivatives. J Chem Pharmaceut Res 2017;9:73–80.
Sulistyowaty, MI, Putra, GS, Budiati, T, Matsunami, K. Synthesis, in vitro anticancer activity and in silico study of some benzylidenehydrazide derivatives. Key Eng Mater 2020;840:277–83.
Thomas, HA. Merck molecular force field. I basis, form, scope, parametrization, and performance of MMFF94. J Comb Chem 1996;17:490–519.
Stamos, J, Sliwkowski, MX, Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;48:46265–72.
Thomsen, R, Christensen, MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006;49:3315–21.
Jayaram, B, Tanya, S, Goutam, M, Abhinav, M, Shashank, S, Vandana, S. Sanjeevini: a freely accessible web-server for target directed lead molecule discovery. BMC Bioinf 2012;13:S7.
Pires, DEV, Blundell, TL, Ascher, DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015;58:4066−72.
Drug Enforcement Administration (DEA). US Department of Justice. Part 1308 — schedules of controlled substances. Link to an amendment published at 85 FR 5322, Jan. 30, 2020.
Undang-Undang Republik Indonesia. Nomor 35 Tahun 2009. About Narkotika. In: Tahun. Jakarta: Penerbit Manuscript; 2009.
Trevor, AJ, Katzung, BG, Kruidering-Hall, M. Katzung and Trevor’s. pharmacology examination & board review, 11th ed. New York: The McGraw-Hill Education; 2015.
Shargel, L, Yu, ABC. Applied biopharmaceutics & pharmacokinetics, 7th ed. New York: The McGraw-Hill Companies; 2016.
BC Cancer Agency Cancer Drug Manual. Erlotinib. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Erlotinib_monograph_1July2014.pdf [Accessed 1 Mar 2019].
Singh, S, Khanna, VK, Pant, AB. Development of in vitro toxicology: a historic story. In: Dhawan, A, Kwon, S, editors. In vitro toxicology. London: Academic Press; 2018.
Wishart, DS, Knox, C, Guo, AC, Shrivastava, S, Hassanali, M, Stothard, P, et al.. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;1:34.
Usdin, E, Efron, DH. Psychotropic drugs and related compounds, 2nd ed. Washington DC: National Institute of Mental Health; 1972.
Batista, R, Júnior, AJS, Braga de Oliveira, A. Plant derived antimalarial agents: new leads and efficient phytomedicines. Part II. Non-alkaloidal natural products. Molecules 2009;14:3037–72.
Cos, P, Vlietinck, AJ, Berghe, DV, Maesa, L. Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept’. J Ethnopharmacol 2006;106:290–302.
National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology non-small cell lung cancer ver.2; 2018. Available from: https://www2.tri-kobe.org/nccn/guideline/lung/english/non_small.pdf [Accessed 1 Jan 2019].